Dugdhika: Benefits, Evidence & Safety

TL;DR

Dugdhika (Euphorbia hirta), the "asthma plant," is used in Ayurveda for respiratory and digestive complaints. Animal studies show increased platelet counts in thrombocytopenic rats and rabbits, and lab studies show weak antibacterial effects. No human clinical trials support its use for asthma or dengue, and human safety data are limited.

(50 words. Sources: Perera et al. 2018 systematic review; Kumar et al. 2010 Pharmacognosy Reviews; JAIMS in-vitro study.)

What it is

Dugdhika is the Sanskrit name for Euphorbia hirta L., a slender-stemmed, annual, hairy plant in the Euphorbiaceae family, growing up to about 40 cm tall and exuding a milky latex when broken (Kumar et al., Pharmacognosy Reviews 2010). The same review lists "dugadhika" among its Sanskrit names and notes the whole plant, especially leaves, is the part used. It is called the "asthma plant" or "pill-bearing spurge" in English and grows as a weed across tropical regions worldwide. Its chemistry includes flavonoids (quercitrin, rutin, quercetin), tannins, triterpenes, and phytosterols (same review).

Traditional use

A systematic review of Ayurvedic literature traces Dugdhika's first detailed mention to the Charaka Samhita, where it appears in formulations for disorders including rajayakshma (wasting), arsha (piles), atisara (diarrhea), and palitya (premature greying). Later Samhitas and Nighantus from the 9th century onward give it increasing prominence with synonyms such as Kshirini and Dudhi (WJPMR textual review, 2025). Traditional uses recorded in the pharmacognosy literature include respiratory ailments (cough, coryza, bronchitis, asthma), dysentery, diarrhea, worm infestations in children, jaundice, and skin conditions (Kumar et al., 2010). These are traditional claims, not clinical proof: the research evidence is assessed separately below.

What modern research says

Dengue and platelet counts (animal evidence, one small uncontrolled human study)

A 2018 systematic review of the scientific evidence for E. hirta in dengue found three animal studies in which subacute administration of the plant increased platelet counts: a decoction of the fresh whole plant (100 mg/kg for 14 days) significantly raised platelet counts and reduced bleeding and clotting time in ethanol-induced thrombocytopenic rats. A water extract of leaves increased mean platelet count by 80% over 9 days in anagrelide-induced thrombocytopenic rats; and expressed juice raised platelet counts within 24 hours in aspirin-induced thrombocytopenic rabbits (Perera et al., Journal of Tropical Medicine 2018).

The same review found only one clinical study: dengue patients admitted to Sir Ganga Ram Hospital, Lahore, given an E. hirta herbal water, in which over 70% showed a platelet increase and marked recovery from fever and flu-like symptoms within 24 hours: but the increase was statistically significant only in the 30–55 age group, not in the 14–25 group, and the study had no proper control comparison (review of Mir et al., 2012). An in-vitro assay found the ethanol leaf extract inhibited dengue virus serotype 2 by 34.7% (same review). There are no randomized controlled trials of E. hirta for dengue in humans.

Antibacterial activity (laboratory only)

An in-vitro study tested fresh leaf juice (swarasa) of Dugdhika against Staphylococcus aureus using the agar well-diffusion method: it produced a 9 mm zone of inhibition when applied directly and 6 mm when diluted: measurable but weaker than the standard drug, and the authors concluded that clinical trials are needed to establish any medicinal benefit in humans (JAIMS, DOI 10.21760/jaims.9.10.5).

Asthma (animal models only)

The plant's "asthma plant" nickname comes from tradition, not trials. A review of its medicinal formulations reports that the methanolic extract of E. hirta significantly reduced airway inflammation, decreased bronchoconstriction, and improved lung function in asthmatic rats, with flavonoids such as quercitrin and rutin proposed as the active agents (European Journal of Medicinal Plants review). No human clinical trials of E. hirta for asthma were identified: the human evidence does not exist yet.

Anti-inflammatory mechanisms (laboratory)

In laboratory work, the aqueous extract strongly reduced the release of prostaglandins I2, E2, and D2, consistent with the anti-inflammatory activity reported in animal models (Kumar et al., 2010).

What the evidence does not support (yet)

There is no human trial evidence that Dugdhika treats asthma, bronchitis, dengue, or infections. It must never replace prescribed asthma medication or standard dengue care. Most claimed effects rest on animal or test-tube studies.

Safety & contraindications

Human safety data for Euphorbia hirta are limited. The plant's milky latex is irritating: traditional sources apply it cautiously, and it should never be applied near the eyes (Kumar et al., 2010). Because the Euphorbia genus includes species with genuinely irritant or toxic sap, correct plant identification matters. There are no adequate data on use in pregnancy or breastfeeding: avoid use in those situations. If you have asthma, discuss any interest in traditional remedies with your doctor and never use them as a replacement for prescribed management, especially during an acute attack, which requires rescue medication or emergency care.

FAQs

Can dugdhika replace my asthma inhaler?

No. There are no human clinical trials of Euphorbia hirta for asthma: only animal studies in which extracts reduced airway inflammation in asthmatic rats (EJMP review). Never rely on it during an asthma attack, which needs fast-acting rescue medication or emergency care.

Does dugdhika raise platelet counts in dengue?

It raised platelet counts in thrombocytopenic rats and rabbits, and one small uncontrolled hospital study reported platelet increases in about 70% of dengue patients: but the effect was statistically significant only in one age group, and there are no randomized controlled trials (Perera et al. systematic review). This is not proven treatment for dengue.

Is dugdhika antibacterial?

Only in the laboratory so far. Fresh leaf juice produced a modest zone of inhibition against Staphylococcus aureus in a petri-dish test, weaker than the standard drug, and the researchers called for clinical trials before any medicinal claim (JAIMS study). Lab activity does not equal effectiveness against infections in people.

Is the milky sap dangerous?

It is irritating. Euphorbia hirta exudes a milky latex that can irritate skin and mucous membranes and must never be applied near the eyes. The wider Euphorbia genus contains species with genuinely toxic sap, so accurate identification matters (Kumar et al., 2010). Keep the plant away from children and pets.

Is dugdhika safe in pregnancy?

There are no adequate human data on Euphorbia hirta in pregnancy or breastfeeding: human safety data are limited overall, so avoid use in those situations and talk to a qualified clinician before considering it. This caution also applies to traditional preparations and combination formulas containing it.

Sources

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.